Meeting
2023 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.
Authors
Revathi Kollipara
Rush University Medical Center, Chicago, IL
Revathi Kollipara , Griffin Budde , Vasily N. Aushev , Elise Kornreich Brunsgaard , Timothy Kuzel , Cristina O'Donoghue , Timothy Riddell , Charuta C. Palsuledesai , Michael Krainock , Minetta C. Liu , Alan Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9582)
DOI
10.1200/JCO.2023.41.16_suppl.9582
Abstract #
9582
Poster Bd #
345
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
First Author: Nyelia Williams
Poster
2021 ASCO Annual Meeting
Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation.
First Author: Bryant Chee
Poster
2021 ASCO Annual Meeting
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
First Author: Jessica Cecile Hassel